Effectiveness of Medication and Combined Medication and Parent Management Training on children with Attention Deficit/Hyperactivity Disorder

Effectiveness of Medication and combined Medication and Parent Management Training on Visuo constructive, Attentional, Behavioral and Emotional Indicators of children with Attention Deficit/Hyperactivity Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013012712302N1

Enrollment

Registered

2013-04-15

Start date

2010-11-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit/Hyperactivity disorder. Other hyperkinetic disorders

Interventions

Intervention 1: group A:medication(MPH)ritalin10mg for 5 weeks. Intervention 2: group B: medication as noted plus 10 sessions of parent management training.

Treatment - Drugs

group A:medication(MPH)ritalin10mg for 5 weeks

group B: medication as noted plus 10 sessions of parent management training

Eligibility

Sex/Gender

All

Age

8 Years to 10 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: Having diagnostic criteria for Attention Deficit/Hyperactivity Disorder ( combined type )according to DSM-IV-TR diagnostic criteria and diagnoses based on child and adolescent psychiatrist and diagnostic criteria required to fill in a questionnaire CSI and T scores above 65 on Scale D from Conners parent rating scale; Having a calendar age of 8 years (boys and girls who have completed their first year of primary school) to 10 years; Lack of medical and psychological treatment during the 1-month; IQ above 90 on the Raven test and the psychiatrist, content, and overall academic records; Enjoying a high school diploma by parents Exclusion criteria : Having epilepsy, mental retardation and pervasive developmental disorders according to psychiatrist, case information, education and testing Raven; Impact of brain damage or prematurity

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visuo constructive index. Timepoint: before intervention and after 5th week of interventin. Method of measurement: bender-gestalt test.;Attentional index. Timepoint: before intervention and after 5th week of intervention. Method of measurement: stroop color- word test.;Emotional indicator. Timepoint: before intervention and after 5th week of intervention. Method of measurement: bender- gestalt test.;Behavioral index. Timepoint: before intervention and after 5th week of intervention. Method of measurement: conners test.	—

Measure

Time frame

Visuo constructive index. Timepoint: before intervention and after 5th week of interventin. Method of measurement: bender-gestalt test.;Attentional index. Timepoint: before intervention and after 5th week of intervention. Method of measurement: stroop color- word test.;Emotional indicator. Timepoint: before intervention and after 5th week of intervention. Method of measurement: bender- gestalt test.;Behavioral index. Timepoint: before intervention and after 5th week of intervention. Method of measurement: conners test.

—

Secondary

Measure	Time frame
IQ. Timepoint: before intervention. Method of measurement: raven test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Fazeli

Tehran University of Medical Siences

zfazeli300@yahoo.comzfazeli300@gmail.com+98 26 3448 0257

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026